Benn Diana E, Croxson Michael S, Tucker Kathy, Bambach Christopher P, Richardson Anne Louise, Delbridge Leigh, Pullan Peter T, Hammond Jeremy, Marsh Deborah J, Robinson Bruce G
Cancer Genetics, Kolling Institute of Medical Research, Royal North Shore Hospital, Syney, NSW, Australia.
Oncogene. 2003 Mar 6;22(9):1358-64. doi: 10.1038/sj.onc.1206300.
Phaeochromocytomas arising in adrenal or extra-adrenal sites and paragangliomas of the head and neck, in particular of the carotid bodies, occur sporadically and also in a familial setting. In addition to mutations in RET and VHL in familial disease, germline mutations in SDHD and SDHB genes that encode subunits of mitochondrial complex II have also been associated with the development of familial phaeochromocytomas. To further investigate the role of SDHD and SDHB in the development of these tumours we determined the occurrence of germline SDHD and SDHB mutations in four patients with a family history of phaeochromocytoma with associated head and neck paraganglioma, one patient with a family history of phaeochromocytoma only and two patients with apparently sporadic extra-adrenal phaeochromocytoma, one of whom had early onset disease. Secondly, we investigated whether somatic SDHB mutations correlated with loss of heterozygosity at 1p36 in a subgroup of 11 sporadic and three MEN 2-associated RET-mutation-positive phaeochromocytomas. Novel SDHB mutations were identified in the probands from four families and two apparently sporadic cases (six of seven probands studied), including two missense mutations, a single nonsense and frameshift mutation, as well as two splice site mutations, one of which was shown to have partial penetrance resulting in 'leaky' splicing. Further, five intronic polymorphisms in SDHB were found. No SDHD mutations were identified. In addition, no somatic SDHB mutations were found in the remaining allele of the 11 sporadic adrenal phaeochromocytomas with allelic loss at 1p36 or the three MEN 2-associated RET-mutation-positive phaeochromocytomas. Therefore, we conclude that SDHB has a major role in the pathogenesis of familial phaeochromocytomas, but the possible role of SDHB in sporadic tumours showing allelic loss at 1p36 has yet to be ascertained.
起源于肾上腺或肾上腺外部位的嗜铬细胞瘤以及头颈部副神经节瘤,尤其是颈动脉体瘤,可散发出现,也可呈家族性发病。除了家族性疾病中RET和VHL的突变外,编码线粒体复合物II亚基的SDHD和SDHB基因的种系突变也与家族性嗜铬细胞瘤的发生有关。为了进一步研究SDHD和SDHB在这些肿瘤发生中的作用,我们确定了4例有嗜铬细胞瘤家族史并伴有头颈部副神经节瘤的患者、1例仅有嗜铬细胞瘤家族史的患者以及2例明显散发的肾上腺外嗜铬细胞瘤患者(其中1例为早发型疾病)种系SDHD和SDHB突变的发生情况。其次,我们研究了11例散发的和3例与MEN 2相关的RET突变阳性嗜铬细胞瘤亚组中,体细胞SDHB突变是否与1p36杂合性缺失相关。在4个家族的先证者和2例明显散发的病例(7例先证者中的6例)中发现了新的SDHB突变,包括2个错义突变、1个无义突变和移码突变,以及2个剪接位点突变,其中1个显示有部分外显率导致“渗漏”剪接。此外,在SDHB中发现了5个内含子多态性。未发现SDHD突变。此外,在11例1p36等位基因缺失的散发肾上腺嗜铬细胞瘤或3例与MEN 2相关的RET突变阳性嗜铬细胞瘤的其余等位基因中未发现体细胞SDHB突变。因此,我们得出结论,SDHB在家族性嗜铬细胞瘤的发病机制中起主要作用,但SDHB在1p36等位基因缺失的散发性肿瘤中的可能作用尚待确定。